| abstract |
The present invention relates to a use of Hades as a tumor suppressor target, and more specifically, to a composition for suppressing tumors, containing as an active ingredient an inhibitor for the expression or action of a Hades protein having the amino acid sequence of SEQ ID NO: 2. The present inventors identified that overexpressed Hades interacts with p53, thereby inhibiting the exonuclear mechanism of p53 and consequently inhibiting the tumor suppressing function of p53, and that the knockdown of Hades increases the expression of p53, and thus first discovered that Hades is a negative regulator of p53. Therefore, if the function of Hades overexpressed in tumor cells is suppressed, the tumor suppressing function of p53 will effectively occur. That is, it is considered that it is possible to develop a suppressor for regulating the expression of a Hades protein or suppressing the action of Hades, and it is also possible to derive drug leads for inhibiting the interaction of Hades and p53 and use the same as an anticancer drug. |